Omarigliptin
Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Omarigliptin
Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.
has abstract
Omarigliptin (MK-3102) is a po ...... ecreases blood glucose levels.
@en
CAS number
1226781-44-7
ChEMBL
FDA UNII code
CVP59Q4JE1
KEGG
PubChem
Wikipage page ID
47,880,585
page length (characters) of wiki page
Wikipage revision ID
963,839,178
Link from a Wikipage to another Wikipage
ATC prefix
None
@en
CAS number
ChEMBL
ChemSpiderID
28,424,182
IUPAC name
KEGG
D10317
@en
legal status
Developing
@en
PubChem
46,209,133
routes of administration
Oral
@en
SMILES
CSn1cc2cCN[C@@H]3C[C@@H]N
@en
StdInChIKey
MKMPWKUAHLTIBJ-ISTRZQFTSA-N
@en
synonyms
MK-3102
@en
UNII
CVP59Q4JE1
@en
wikiPageUsesTemplate
hypernym
comment
Omarigliptin (MK-3102) is a po ...... ecreases blood glucose levels.
@en
label
Omarigliptin
@en